ログインで組織・契約価格をご覧ください。
サイズを選択してください
表示を変更する
この商品について
実験式(ヒル表記法):
C11H16ClN5·HCl
CAS番号:
分子量:
290.19
NACRES:
NA.77
PubChem Substance ID:
UNSPSC Code:
51101906
EC Number:
211-283-7
MDL number:
Quality Level
assay
≥95% (HPLC)
form
solid
storage condition
desiccated
solubility
acetonitrile: water: ~1 mg/mL (60/40)
originator
AstraZeneca
storage temp.
2-8°C
SMILES string
Cl.CC(C)NC(=N)NC(=N)Nc1ccc(Cl)cc1
InChI
1S/C11H16ClN5.ClH/c1-7(2)15-10(13)17-11(14)16-9-5-3-8(12)4-6-9;/h3-7H,1-2H3,(H5,13,14,15,16,17);1H
InChI key
SARMGXPVOFNNNG-UHFFFAOYSA-N
Application
Proguanil (chlorguanide) may be used in anti-parasitic protozoan drug development to study its pharmacokinetics, metabolism, safety, efficacy and methods of delivery as an antimalarial drug.
Biochem/physiol Actions
塩酸プログアニルは抗マラリア薬です。ジヒドロ葉酸レダクターゼ阻害剤です。
Chlorguanide (proguanil) is combined with atovaquone for malaria prophylaxis. The two compounds act synergistically to inhibit the plasmodial dihydrofolate reductase (DHFR) and interrupt the electron transport chain. Mutations in DHFR account for the development of resistant strains.
Features and Benefits
This compound was developed by AstraZeneca. To browse the list of other pharma-developed compounds and Approved Drugs/Drug Candidates, click here.
Still not finding the right product?
Explore all of our products under プログアニル 塩酸塩
signalword
Danger
hcodes
Hazard Classifications
Acute Tox. 3 Oral
保管分類
6.1C - Combustible acute toxic Cat.3 / toxic compounds or compounds which causing chronic effects
wgk
WGK 3
flash_point_f
Not applicable
flash_point_c
Not applicable
適用法令
試験研究用途を考慮した関連法令を主に挙げております。化学物質以外については、一部の情報のみ提供しています。 製品を安全かつ合法的に使用することは、使用者の義務です。最新情報により修正される場合があります。WEBの反映には時間を要することがあるため、適宜SDSをご参照ください。
G7048-BULK: + G7048-10MG: + G7048-VAR: + G7048-50MG:
jan
資料
Bioactive small molecules for immune system signaling target identification/validation and antibiotics, antivirals, and antifungals offered.
Laura C Steinhardt et al.
The American journal of tropical medicine and hygiene, 85(6), 1015-1024 (2011-12-07)
Because of recent declining malaria transmission in Latin America, some authorities have recommended against chemoprophylaxis for most travelers to this region. However, the predominant parasite species in Latin America, Plasmodium vivax, can form hypnozoites sequestered in the liver, causing malaria
M Cella et al.
Clinical pharmacology and therapeutics, 91(4), 718-725 (2012-03-09)
In this investigation we evaluate the relevance of a model-based approach for pharmacokinetic (PK) bridging and dose selection of drug combinations in children. The fixed-dose combination of atovaquone (ATV) and proguanil (PGN) was used for illustration purposes. A population PK
Anne C Teirlinck et al.
The Journal of infectious diseases, 207(4), 656-660 (2012-11-29)
We established a new field clone of Plasmodium falciparum for use in controlled human malaria infections and vaccine studies to complement the current small portfolio of P. falciparum strains, primarily based on NF54. The Cambodian clone NF135.C10 consistently produced gametocytes
